JOINN Laboratories (China) Co., Ltd. Class H (HK:6127)
:6127
6127 Stock Chart & Stats
HK$21.12
HK$0.01(0.12%)
At close: 4:00 PM EST
HK$21.12
HK$0.01(0.12%)
Day’s Range― - ―
52-Week RangeHK$9.36 - HK$28.70
Previous CloseN/A
Volume546.17K
Average Volume (3M)6.46M
Market Cap
HK$28.49B
Enterprise ValueHK$26.03B
Total Cash (Recent Filing)HK$2.63B
Total Debt (Recent Filing)HK$1.42M
Price to Earnings (P/E)46.3
Beta1.40
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.15%
Share Statistics
EPS (TTM)0.34
Shares Outstanding118,995,210
10 Day Avg. Volume2,397,586
30 Day Avg. Volume6,458,364
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.65
Price to Sales (P/S)8.31
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$16.80Price Target Upside-20.45% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)0.57
Revenue Forecast (FY)HK$2.13B
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthExtremely low leverage and a large equity base materially reduce financial distress risk. This conservative capitalization supports sustained operations, funds discretionary investment or buybacks, and preserves strategic optionality during multi-quarter revenue weakness or industry cyclicality.
Consistent Free Cash FlowRepeatable free cash generation provides internal funding for R&D, compliance, and capacity without reliance on external financing. Over 2–6 months this underpins dividend capacity and operational stability, enabling the firm to service clients and maintain labs during top-line volatility.
Structural CRO DemandAs a CRO focused on preclinical services, JOINN sits within a durable outsourcing trend where biopharma increasingly externalizes non-core lab work. This business model yields repeat project pipelines, high client switching costs, and long-term secular demand tied to global R&D spend.
Bears Say
Severe Revenue ContractionA dramatic two-year top-line decline sharply reduces scale economics and threatens long-run client relationships. Sustained or recurring revenue drops impair capacity utilization, pressure per-study pricing, and make multi-quarter recovery uncertain absent clear new contract wins.
Inconsistent Cash ConversionLarge gaps between net income and operating cash flow point to working-capital or timing issues that degrade earnings quality. Over months this complicates forecasting, can constrain reinvestment or dividend smoothing, and raises the probability of short-term liquidity strain if revenue remains weak.
Profitability And ROE VolatilityWhile margins recovered, the swings across years indicate profitability is highly sensitive to revenue mix and utilization. Modest ROE even after rebound suggests returns on capital are limited when revenue falters, reducing capacity to self-fund growth and making long-term return consistency questionable.
JOINN Laboratories (China) Co., Ltd. Class H News
6127 FAQ
What was JOINN Laboratories (China) Co., Ltd. Class H’s price range in the past 12 months?
JOINN Laboratories (China) Co., Ltd. Class H lowest stock price was HK$9.36 and its highest was HK$28.70 in the past 12 months.
What is JOINN Laboratories (China) Co., Ltd. Class H’s market cap?
JOINN Laboratories (China) Co., Ltd. Class H’s market cap is HK$28.49B.
When is JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date?
JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date is Apr 30, 2026 which is in 21 days.
How were JOINN Laboratories (China) Co., Ltd. Class H’s earnings last quarter?
JOINN Laboratories (China) Co., Ltd. Class H released its earnings results on Mar 30, 2026. The company reported HK$0.336 earnings per share for the quarter, the consensus estimate of HK$0.336 by HK$0.
Is JOINN Laboratories (China) Co., Ltd. Class H overvalued?
According to Wall Street analysts JOINN Laboratories (China) Co., Ltd. Class H’s price is currently Overvalued.
Does JOINN Laboratories (China) Co., Ltd. Class H pay dividends?
JOINN Laboratories (China) Co., Ltd. Class H pays a Annually dividend of HK$0.033 which represents an annual dividend yield of 0.15%. See more information on JOINN Laboratories (China) Co., Ltd. Class H dividends here
What is JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate?
JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JOINN Laboratories (China) Co., Ltd. Class H have?
JOINN Laboratories (China) Co., Ltd. Class H has 118,995,210 shares outstanding.
What happened to JOINN Laboratories (China) Co., Ltd. Class H’s price movement after its last earnings report?
JOINN Laboratories (China) Co., Ltd. Class H reported an EPS of HK$0.336 in its last earnings report, expectations of HK$0.336. Following the earnings report the stock price went up 2.69%.
Which hedge fund is a major shareholder of JOINN Laboratories (China) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6127
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JOINN Laboratories (China) Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.02%
12-Months-Change
Fundamentals
Return on Equity
3.65%
Trailing 12-Months
Asset Growth
7.84%
Trailing 12-Months
Company Description
JOINN Laboratories (China) Co., Ltd. Class H
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers investment management and cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.
6127 Stock 12 Month Forecast
Average Price Target
HK$16.80
▼(-20.45% Downside)
Technical Analysis
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Shanghai Conant Optical Co. Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―
Options Prices
Currently, No data available
---